You
are here: Home: Meet
The Professors Vol. 1 2003: Case
4
|
• |
Patient in her 30s with a past history of a positive
tuberculin test (no treatment for TB) |
• |
Lumpectomy, axillary dissection at another hospital
for a 5-cm ER/PR-negative, HER2-negative (IHC by outside lab)
left breast cancer (7/7 positive nodes) |
• |
Postoperative examination: Left breast tenderness
at surgical site |
• |
Disabled by aseptic necrosis of right hip unrelated
to breast cancer |
• |
Chest X-Ray: Multiple, nonspecific nodules too
small to biopsy |
• |
Repeat TB test: Positive |
• |
Started TAC chemotherapy |
• |
Developed staphylococcal bacteremia from infected
port-a-cath within the first week of treatment before blood
counts fell |
• |
Treatment delayed 3-4 weeks, port-a-cath removed
and resistant staphylococcal infection treated |
• |
Pulmonary nodules increased in size and there
was swelling in left breast and increasing pain and tenderness |
• |
FNA of pulmonary nodules: Positive for metastatic
adenocarcinoma |
• |
Ultrasound of tumor cavity: Solid elements present |
• |
Core breast biopsies: Positive for residual cancer,
ER/PR-negative, but HER2- positive (IHC 3+) |
|
|
|
Key discussion points: |
|
|
HER2-testing with IHC versus
FISH |
|
Selection of chemotherapy
in combination with trastuzumab in patients with HER2- positive
metastatic disease |
|
Monitoring cardiac function
in patients on trastuzumab |
|
Carboplatin versus cisplatin |
|
Duration of trastuzumab therapy |
|
Scheduling of taxane/carboplatin
combination |
Dr Love: Tell us a little bit
more about this woman, her attitude, and how she and her family
reacted to the news of her metastatic disease?
Dr Cohen: She was depressed
during the separation from her family when she was hospitalized
for the staphylococcal bacteremia. She was not very talkative and
just laid in bed, sleeping most of the time. After she was able
to leave the hospital and move around, she was much more animated.
When we talked about the lung disease she realized she had metastatic
disease and asked whether she was going to be cured. I had to convert
the discussion from one of cure to control and prolongation of
her life in the best possible way. She understood, but it set her
back for a while. Her husband was extremely supportive; they have
a very strong, mutually supportive relationship.
Dr Love: Dr Cohen, were you
concerned that HER2-negative status of her primary tumor may have
been incorrect? Did you consider submitting her tumor for analysis
by FISH?
Dr Cohen: We did not obtain
a FISH due to financial concerns. If we were going to send it out,
she would have been required to sign a financial obligation to
pay for anything that wasn’t covered by insurance, and she
refused to do that.
Dr Perez: We
cannot forget the financial burden that some tests and therapies
we recommend might have on patients and families. In this particular
situation, knowing the HER2 status is critical to making an appropriate
recommendation, and I’m not completely comfortable that this
patient has HER2-positive disease. I would want to review the initial
slides to determine whether a mistake was made in the immunohistochemistry.
Perhaps a review of those slides wouldn’t cost as much as
ordering FISH.
Dr Cohen: We did review the
initial slides, but our pathologist agreed with the histologic
diagnosis, and we didn’t repeat the biopsy at that time.
This is one reason I decided to rebiopsy the lesion when she was
not doing well. I wanted the IHC done in our lab — our lab’s
IHC 3+ results have all been positive on FISH.
Dr Perez: Good. If the pathology
has been evaluated in a laboratory like yours, with a high volume
of HER2 testing corroborated with FISH analysis, then I would be
content that this patient’s tumor is HER2-positive based
on immunohistochemistry. If her test is read as IHC 3+, I do not
see any need to corroborate that with FISH analysis. Clinical trials
have demonstrated that the benefit of trastuzumab is similar for
patients with IHC 3+ positivity or FISH positivity, so, I wouldn’t
go any further in terms of retesting her tumor.
Dr Robert: As
a former pathologist, I must add that immunohistochemistry is much
easier and less expensive than FISH, and FISH usually has to be
sent out. However, IHC has to be done by a high-volume pathology
department to be reproducible. We have a financial block in our
thinking that an inexpensive immunohistochemistry test is adequate
and we don’t want to spend money on FISH, yet we’re
willing to give trastuzumab, which has a significant cost.
In reviewing Dr Chuck Vogel’s experience with first-line
single-agent trastuzumab (Table 5, page 26) and Dr Melody Cobleigh’s
experience with trastuzumab given after chemotherapy — of
the IHC 3+ patients who responded, only one patient out of more
than 60 was not FISH-positive. There is a very good linkage between
FISH positivity and response to trastuzumab.
It has become my routine practice in metastatic breast cancer,
not to be comfortable with IHC evaluation but to order a FISH test.
The flip side is also true — patients with IHC 1+ or 2+ tumors
that are FISH-positive have a very good chance of responding to
trastuzumab.
Dr Capistrano: We
know that our laboratory has a good correlation between IHC 3+
and FISH positivity. But, for example, if you send an IHC 2+ to
the reference laboratory and they can’t make a decision about
a tumor being FISH-positive or not, would you subject that patient
to the potential risks of long-term trastuzumab?
Dr Perez: That is a very good
question. Sometimes, technically, it’s impossible to obtain
a result of the test — even in big laboratories. A CALGB
study led by Andy Seidman will help us address this issue (Figure
3). They are enrolling patients with HER2-positive or HER2-negative
breast cancer to receive paclitaxel either alone or with trastuzumab.
This trial is almost complete, so we’ll eventually have an
answer. At this point, I have not treated patients with HER2-negative
breast cancer with trastuzumab.
We know that a percentage of IHC 2+ tumors are actually FISH-positive.
In a study we did at the Mayo Clinic — in more than 200 specimens
tested as IHC 2+ (the largest study to date) — we found a
12 percent rate of FISH positivity. More data will be forthcoming
in the next couple of years regarding that issue.
Dr Love: Dr Perez, how would
you treat this patient?
Dr Perez: The FDA indication
for trastuzumab in combination with chemotherapy is based on the
pivotal study done with weekly trastuzumab and paclitaxel given
every three weeks, which demonstrated improvement in response rate,
time to progression, one-year survival, and median survival (Figure
4). Since that pivotal trial was completed, many other Phase II
studies have been published, and a Phase III trial led by Dr Nick
Robert provides data on carboplatin with paclitaxel and trastuzumab.
I would treat this patient first-line with paclitaxel, carboplatin
and trastuzumab. I also believe Dr Cohen’s decision to use
adjuvant TAC chemotherapy at the initial diagnosis was appropriate.
Dr Love: In which patients with
HER2-positive metastatic disease would you use trastuzumab alone
or with some other chemotherapy? What about this woman’s
disease is causing you to use the full triplet?
Dr Perez: Despite the excellent
data published by Dr Chuck Vogel using single-agent trastuzumab
(Table 5), I’ve actually never used trastuzumab alone in
my practice. If a patient has hormone receptor-positive breast
cancer that is HER2-positive, I tend to use hormonal therapy rather
than first-line trastuzumab or trastuzumab in combination with
hormonal therapy. I try to extend the duration of hormonal therapy
as long as possible. In a patient like this, with a rapidly progressive
tumor, I want to rely on the best therapy I have with the highest
possibility of tumor control right away.
Dr Love: What if this woman
was in her 70s rather than her 30s?
Dr Perez: I would use the same
approach regardless of the patient’s age. Actually, in our
original paclitaxel and carboplatin study, we had patients up to
82 years of age. I use the patient’s physiological condition,
rather than chronologic age, to make these decisions. The velocity
of growth and the site of tumor involvement guide my approach.
Dr Love: Nick, what are your
thoughts about single-agent trastuzumab, and how would you have
thought through this case?
Dr Robert: HER2-positive metastatic
breast cancer is usually an aggressive disease, but there are patients
in whom it isn’t aggressive. In cases of slowly progressing,
ER-positive disease, we often give endocrine agents and delay chemotherapy
even though chemotherapy might produce a faster response or a higher
response rate. Similarly, there will be patients with slowly progressive
HER2-positive disease who can be treated with trastuzumab monotherapy
for a period of time.
This patient, however, is a young woman with aggressive Stage
IV disease. I agree that trastuzumab with chemotherapy is the most
appropriate combination, given the pivotal trial data demonstrating
that trastuzumab with chemotherapy produces a better response rate,
time to progression, and overall survival than chemotherapy alone.
Keep in mind that this trial had two chemotherapy arms — doxorubicin/cyclophosphamide/trastuzumab
versus paclitaxel/trastuzumab.
Next page
Page 1 of 2
|